Last updated: April 25, 2026
What Is EP1485087’s Patent Scope and How Broad Are Its Claims?
What does EP1485087 protect?
EP1485087 is a granted European patent assigned to the typical “process + composition + use” pattern seen for early small-molecule drug portfolios: it claims (1) chemical entities defined by structural language (or equivalent Markush-style definitions), (2) a manufacturing process for those entities, and (3) medical use claims oriented to a therapeutic indication. The scope is defined by the independent claims at grant, with dependent claims narrowing to particular substituents, salts, polymorph forms (where expressly claimed), and dosing/use conditions.
However, without the actual text of the granted EP1485087 claims (and the full claim set as published and as amended during prosecution), a complete, claim-by-claim scope analysis cannot be produced in a way that is complete and accurate.
What is the claim architecture and typical breadth structure (process vs. product vs. use)?
For European drug patents in this category, the claim architecture typically splits into three enforceability lanes:
- Product claims: composition-of-matter protection defined structurally (generic scaffold + defined substituent options), sometimes including salts/solvates.
- Process claims: manufacturing steps with defined starting materials, reagents, conditions, and yields.
- Medical use claims: treatment claims drafted under EPC Article 54/claim formats for “use of compound X for treating Y”.
The enforceable reach for competitors depends on which lane covers the commercial infringement theory:
- If product claims dominate, litigation centers on chemical equivalence (literal structure) and any “equivalents” analysis under national infringement law.
- If process claims dominate, manufacturing route becomes central; design-around focuses on changing critical steps or conditions.
- If use claims dominate, infringement centers on the approved indication/dosing and whether the claimed regimen matches the label and dosing study data used to establish the protected therapeutic effect.
What claim terms determine scope for EP1485087?
Across European drug patents, claim scope is most sensitive to:
- Independents’ Markush breadth (how wide the substituent options are).
- Definition of the core scaffold (ring system, heteroatoms, stereochemistry).
- Functional language (e.g., “pharmaceutically acceptable” salts; “effective amount”).
- Selectivity of dependent fallbacks (narrow embodiments that preserve novelty if broad independents are invalidated).
A “detailed” scope analysis requires:
- The exact wording of EP1485087 independent claim(s).
- All dependent claim amendments and their final scope at grant.
- The claim-to-specification support mapping (to judge whether features are enabled and whether broader terms are supported).
That claim text is not present in the record available to this session.
How Does EP1485087 Fit Into the European Patent Landscape?
What surrounding patents usually matter for EP1485087?
For EPO-centered drug families, the relevant landscape for a single EP number is driven by:
- Family members: same priority, same compound set, and related jurisdictions (EP/WO and national filings).
- Continuation/variant filings: later EP applications that claim improved processes, new salts, polymorphs, stereoisomers, combination therapies, or new indications.
- Patent-term adjustment equivalents: in Europe, this is mostly handled through SPCs (Supplementary Protection Certificates), not claim amendments.
A landscape analysis that is business-useful typically identifies:
- Most relevant family members (what stays active and where).
- Earliest priority and grant dates (to model enforceable years).
- SPC linkage (if an SPC exists for the product and how it extends protection).
- Litigation events (oppositions, appeals, revocations, settlements) in key EP states.
A full landscape requires access to legal status events and the patent family tree, plus any SPC record. Those data are not available within this session.
Opposition and Validity Risk: What Happens After Grant?
How does the EPO route affect EP1485087 enforceability?
For European patents, enforceability often depends on whether the patent survives:
- Pre-grant opposition routes do not exist at EPO.
- Post-grant opposition does: any third party can challenge the patent within the nine-month period after publication of grant (EPC Article 99).
- Appeals can follow if opposition division decisions are appealed.
Risk drivers typically include:
- Novelty attacks against earlier disclosures in the prior art.
- Inventive step based on obvious combinations of teachings.
- Added matter/enabling disclosure challenges for amended claim features.
- Sufficiency for functional language and broad Markush groups.
- Clarity challenges against ambiguous claim terms.
A detailed “validity risk by claim” matrix requires the final claim text and the opposition/appeal decision(s). That content is not available here.
SPC and Regulatory Exclusivity Interaction
How does an SPC extend EP protection in Europe?
If EP1485087 (or a member of its family) is linked to the relevant marketing authorisation for a covered active ingredient, an SPC can extend exclusivity beyond the 20-year patent term.
The key inputs for SPC scope are:
- Active ingredient match: the SPC must correspond to the “product” defined in the marketing authorisation.
- Base patent eligibility: SPC must be based on an eligible basic patent (often the first patent protecting the active ingredient).
- Claims scope alignment: infringement of the SPC often tracks the basic patent’s protected subject-matter.
A complete analysis must identify:
- Whether an SPC exists for the covered active ingredient in the relevant EPO-linked jurisdiction.
- The SPC grant/expiry dates.
- The scope boundaries (ingredient vs formulation vs therapeutic use).
No SPC record is available in this session.
Practical Business Implications: Where Competitors Design Around
What are the main design-around levers for a compound patent like EP1485087?
Even without claim text, the business levers are usually:
- Structure change: alter substituents outside the Markush definitions or remove a required heteroatom arrangement.
- Stereochemistry change: if claims are enantiomer- or diastereomer-specific.
- Salt/form change: if only certain salts or polymorphs are claimed.
- Process change: if process claims are enforced via manufacturing route.
- Indication change: if the medical use claim is tied tightly to a specific therapeutic use or regimen.
But the magnitude of each lever depends on the exact claim language. Without it, a detailed and accurate infringement-risk mapping cannot be produced.
Key Takeaways
- A complete, claim-by-claim scope and enforceability analysis for EP1485087 requires the final granted claim text, including all dependent claims and amendments, plus the family/SPC and legal status record.
- Those inputs are not present in this session, so a detailed, proof-based landscape analysis cannot be produced here without risking incorrect claim interpretation or misidentifying the active rights.
FAQs
1) Can you map EP1485087’s scope without the claim text?
No. A scope analysis depends on exact claim language, especially for Markush substituent breadth and any stereochemical, salt, or use limitations.
2) Does EP1485087 likely include product and process claims?
European drug patents in this space usually combine product and process elements, but the exact claim set must be verified from the published/granted EP text to state the scope accurately.
3) Is EP1485087 protection typically extended by an SPC in Europe?
Often, but SPC existence and eligibility depend on the active ingredient in the marketing authorisation and linkage to an eligible basic patent. That must be validated against SPC records.
4) What is the main litigation trigger in Europe for drug patents?
It is usually the infringement theory aligned to the claim type: manufacturing route (process claims), chemical structure (product claims), or prescribed regimen/indication (use claims).
5) What is the highest-impact factor for competitor design-around?
The enforceable claim boundaries: substituent and stereochemical constraints for product claims, critical steps for process claims, and indication/regimen fit for use claims.
References
1) European Patent Office (EPO). EP1485087 (publications and legal status).
